<DOC>
	<DOCNO>NCT00830570</DOCNO>
	<brief_summary>The purpose quasi-experiment study , could also classify prospective observational intervention study , assess impact cytochrome P450 2C9 ( CYP 2C9 ) vitamin K epoxide reductase complex , subunit 1 ( VKORC1 ) test within primary patient care set .</brief_summary>
	<brief_title>The Clinical Economic Impact Pharmacogenomic Testing Warfarin Therapy Typical Community Practice Settings</brief_title>
	<detailed_description>Anticoagulation therapy warfarin common mode treatment prophylaxis venous arterial thromboembolic condition . Warfarin metabolize liver cytochrome P450 system , cytochrome P450 2C9 ( CYP 2C9 ) isoenzyme specifically , polymorphism CYP 2C9 gene associate change metabolic function translate isoenzyme . These polymorphism result reduce metabolism warfarin compare subject wild type gene , consequently lead systemic accumulation warfarin ; theorize lead high risk adverse event . Other allelic variation also link change vitamin K conservation effect vitamin K epoxide reductase complex , subunit 1 ( VKORC1 ) . The combined impact CYP 2C9 VKORC1 polymorphisms warfarin 's pharmacology recently report . It hypothesize evaluation genomic allelic type guide warfarin dose reduce thromboembolic bleeding risk associate warfarin therapy , adoption genetic test strategy primary patient care set would improve warfarin effectiveness patient safety , reduce cost health care payer .</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Embolism Thrombosis</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Female male age range 4075 Patients induction phase warfarin Patients receive warfarin prevent treat thromboembolic condition ( e.g. , post orthopedic surgery prophylaxis , deep venous thrombosis , atrial fibrillation , pulmonary embolism , heart failure ) Patient willing provide inform consent prior specimen collection procedure Patient whose physician willing order genetic test Age &lt; 40 &gt; 75 Previous use warfarin within 180 day initiate new warfarin therapy Hospitalized seven day first claim warfarin Previous history genetic test warfarin therapy Known hypersensitivity warfarin Patient physician refusal participate study Patients use warfarin residing Olmsted County , MN</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>CYP2C9</keyword>
	<keyword>VKORC1</keyword>
	<keyword>polymorphism</keyword>
	<keyword>warfarin</keyword>
	<keyword>Coumadin</keyword>
</DOC>